

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Application No. 10/511,885	)	
		)	
Filed:	October 19, 2004	)	<b>Confirmation No. 4212</b>
		)	
Applicant:	Martin PURPURA et al.	)	
		)	
Title:	FUNCTIONAL FOODS	)	This Information Disclosure Statement
	CONTAINING A PHOSPHOLIPID-	)	was electronically filed on June 17, 2009
	CONTAINING STABLE MATRIX	)	using the USPTO's EFS-Web.
		)	
Art Unit:	1615	)	
		)	
Examiner:	Snigdha MAEWALL	)	
		)	
Attorney Docket:	5942/83616	)	
		)	
Customer No.:	22242	)	

Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Even though the Examiner is well aware of the first application set forth below and because applicants desire to have that application cited on the face of any patent issuing from the application, applicants and the undersigned attorney bring the following commonly-owned, co-pending application to the attention of the Examiner (as well as the art cited on the applications identified below):

- U.S. Patent Application No. 10/511,884, which entered the U.S. national phase on October 19, 2004, from PCT/EP03/04031, filed April 17, 2003 (Attorney Docket No. 83615), entitled "Physiologically compatible, phospholipid-containing, stable and hard matrix."

Application No. 10/511,885  
INFORMATION DISCLOSURE STATEMENT


- U.S. Patent Application No. 10/511,888, which entered the U.S. national phase on October 19, 2004, from PCT/EP03/04030, filed April 17, 2003 (Attorney Docket No. 83518), entitled "Matrix comprising a bioactive component containing phospholipid."
- U.S. Patent Application No. 10/491,636, which entered the U.S. national phase on April 2, 2004, from PCT/EP02/11124, filed October 4, 2002 (Attorney Docket No. 82647), entitled "Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)."

Pursuant to 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees which may be required with respect to this communication, or credit any overpayment, to Deposit Account No. 06-1135.

Respectfully submitted,  
FITCH, EVEN, TABIN & FLANNERY

Dated: June 17, 2009

  
Timothy E. Levstik  
Registration No. 30,192

120 South LaSalle Street, Suite 1600  
Chicago, Illinois 60603-3406  
Telephone (312) 577-7000  
Facsimile (312) 577-7007  
536373